Sells orthopedic devices for injury prevention, pain management and rehabilitation to healthcare professionals and patients, and joint-replacement implants and surgical tools to surgeons and healthcare systems.
10-K for FY2025, filed Feb 26, 2026We report our operations through the Prevention & Recovery (“P&R”) and Reconstructive segments (“Recon”). We develop, manufacture and…View ↗
Our P&R segment includes products that are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists…View ↗
Our Recon segment is a global medical technology business focused on developing, manufacturing, marketing, and distributing innovative…View ↗
Customers buy medical devices and related products, with billing generally occurring when off-the-shelf products ship.
10-K for FY2025, filed Feb 26, 2026
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by reportable segment ↗$2.2B
10-K for FY2025, filed Feb 26, 2026
$2.2B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Prevention & Recovery:
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
51%
FY2022: 66%
|
Prevention & Recovery:, FY2025
$1.1B Sources
|
Sold outright |
|
Reconstructive:
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
49%
FY2022: 34%
|
Reconstructive:, FY2025
$1.1B Sources
|
Sold outright |
Healthcare professionals and hospitals are served through independent distributors, dealers and direct salespeople; retail consumers are also reached through direct-to-consumer channels.
10-K for FY2025, filed Feb 26, 2026
Not on paper. It lost $1.2B in FY2025, but brought in more cash than it spent: $19.9M of free cash flow.
10-Q for Q3 FY2026, filed Nov 5, 2026
$3.1MView ↗
8-K, filed Sep 1, 2026
On August 31, 2026, Enovis Corporation (the “Company”) entered into a binding offer to acquire eCential Robotics SAS (“eCential”), a…View ↗
8-K, filed Aug 6, 2026
Second-quarter sales growth of 3% on a reported basis, 5% organic Second-quarter Reconstructive sales growth of 8% on a reported basis, 6%…View ↗
Growing. Revenue grew 58% in 4 years, from $1.4B in FY2021 to $2.2B in FY2025, about 12% a year.
Competes with Össur, Breg, Stryker, Zimmer Biomet, and Johnson & Johnson
10-K for FY2025, filed Feb 26, 2026Our Prevention & Recovery segment generates approximately 67% of its revenues in the U.S. and the majority of the remaining balance in…View ↗
Loading...